Journal
SEMINARS IN IMMUNOLOGY
Volume 56, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2021.101541
Keywords
Immunoengineering; Immunotherapy; Nanoparticle; T cell; Bioengineering; Cell therapy
Categories
Funding
- National Institutes of Health [P41EB028239, R21AI160738]
- National Science Foundation [DGE-1746891]
- ARCS Foundation Metro Washington Chapter
Ask authors/readers for more resources
Nanoparticles offer a versatile platform to enhance the efficacy of T cell therapy by improving cell targeting and internalization capabilities. They can enhance antigen-specific T cell responses at each step, potentially replacing endogenous cells in the process.
T cell therapy shows promise as an immunotherapy in both immunostimulatory and immunosuppressive applications. However, the forms of T cell-based therapy that are currently in the clinic, such as adoptive cell transfer and vaccines, are limited by cost, time-to-treatment, and patient variability. Nanoparticles offer a modular, universal platform to improve the efficacy of various T cell therapies as nanoparticle properties can be easily modified for enhanced cell targeting, organ targeting, and cell internalization. Nanoparticles can enhance or even replace endogenous cells during each step of generating an antigen-specific T cell response - from antigen presentation and T cell activation to T cell maintenance. In this review, we discuss the unique applications of nanoparticles for antigen-specific T cell therapy, focusing on nanoparticles as vaccines (to activate endogenous antigen presenting cells (APCs)), as artificial Antigen Presenting Cells (aAPCs, to directly activate T cells), and as drug delivery vehicles (to support activated T cells).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available